These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 29030417)

  • 1. Reply to 'Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes' by Yoshimoto
    León Jiménez D; Pérez Temprano R; Ruiz Hueso R; Lopéz Chozas JM; Miramontes González JP
    J Investig Med; 2018 Feb; 66(2):e4. PubMed ID: 29030417
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.
    Yoshimoto T; Furuki T; Kobori H; Miyakawa M; Imachi H; Murao K; Nishiyama A
    J Investig Med; 2017 Oct; 65(7):1057-1061. PubMed ID: 28596160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
    Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
    PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.
    Ishibashi Y; Matsui T; Yamagishi SI
    Diab Vasc Dis Res; 2016 Nov; 13(6):438-441. PubMed ID: 27407083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease.
    Tiryaki Ö; Usalan C; Sayiner ZA
    Ren Fail; 2016; 38(2):222-7. PubMed ID: 26707134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.
    Steen O; Goldenberg RM
    Can J Diabetes; 2017 Oct; 41(5):517-523. PubMed ID: 28942789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary Angiotensinogen and Renin Excretion are Associated with Chronic Kidney Disease.
    Juretzko A; Steinbach A; Hannemann A; Endlich K; Endlich N; Friedrich N; Lendeckel U; Stracke S; Rettig R
    Kidney Blood Press Res; 2017; 42(1):145-155. PubMed ID: 28395289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Urinary Angiotensinogen Associated with Deterioration of Kidney Function in Patients with Type 2 Diabetes Mellitus.
    Lee MJ; Kim SS; Kim IJ; Song SH; Kim EH; Seo JY; Kim JH; Kim S; Jeon YK; Kim BH; Kim YK
    J Korean Med Sci; 2017 May; 32(5):782-788. PubMed ID: 28378551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
    Persson F; Lu X; Rossing P; Garrelds IM; Danser AH; Parving HH
    J Hypertens; 2013 Aug; 31(8):1646-52. PubMed ID: 23743807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?
    Chan GCW; Tang SCW
    Kidney Int; 2018 Jan; 93(1):22-24. PubMed ID: 29291819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.
    Morillas C
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():49-53. PubMed ID: 28760226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Shi H; O'Gorman M; Zhou Z; Cutler DL
    J Clin Pharmacol; 2017 Nov; 57(11):1432-1443. PubMed ID: 28703316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients.
    Kim SS; Song SH; Kim IJ; Yang JY; Lee JG; Kwak IS; Kim YK
    Diabetes Res Clin Pract; 2012 Aug; 97(2):251-7. PubMed ID: 22440044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease.
    Burns KD; Cherney D
    Am J Nephrol; 2019; 49(4):328-330. PubMed ID: 30921790
    [No Abstract]   [Full Text] [Related]  

  • 18. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
    Škrtić M; Cherney DZ
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):96-103. PubMed ID: 25470017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased urinary angiotensinogen precedes the onset of albuminuria in normotensive type 2 diabetic patients.
    Zhuang Z; Bai Q; A L; Liang Y; Zheng D; Wang Y
    Int J Clin Exp Pathol; 2015; 8(9):11464-9. PubMed ID: 26617876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
    Yassin SA; Aroda VR
    Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.